Analysis of US Patent 6,143,326: Scope, Claims, and Patent Landscape
What Does US Patent 6,143,326 Cover?
US Patent 6,143,326, granted on November 7, 2000, holds claims related to a specific pharmaceutical composition and its method of use. The patent primarily covers a method of treating hypercholesterolemia with a combination of certain statins and other agents, along with related formulations.
Patent Scope
The patent's claims focus on:
-
A composite pharmaceutical composition that comprises a statin (e.g., lovastatin, pravastatin, simvastatin) combined with another agent (e.g., a fibrate or other lipid-lowering drug).
-
A method of treating hypercholesterolemia by administering such a composition in an effective amount.
-
Specific dosage ranges and administration protocols.
The claims extend to:
-
Different formulations such as pills and capsules.
-
Methods involving simultaneous or sequential administration.
-
Specific patient populations, particularly those with elevated LDL cholesterol levels.
Key Claims
-
Claim 1: A method of lowering cholesterol in a patient by administering a combination of a statin and a fibrate.
-
Claims 2-5: Defined dosage ranges, administration regimens, and specific statin/fibrate pairings.
-
Claims 6-8: Compositions that include the active ingredients in specific ratios.
The language emphasizes combination therapy for improved efficacy over monotherapy.
Patent Landscape and Related Patents
Patent Family and Chain
US 6,143,326 is part of a patent family covering combination lipid-lowering therapies:
| Patent Number |
Issue Date |
Country |
Focus |
| US 6,143,326 |
11/07/2000 |
US |
Combination of statin and fibrate |
| EP 0957051 |
11/29/2000 |
Europe |
Equivalent European patent, claims similar |
| WO 99/67963 |
12/02/1999 |
WO |
International patent application |
Cited Patents and Art
The patent cites key prior art, including:
- US Patent 4,627,977 directed to lipid-lowering compositions.
- US Patent 5,840,695 covering fibrate and statin combinations.
- Literature on combination lipid therapy and clinical trials.
Patentability Considerations
-
Novelty: The combination of statins and fibrates was known before 2000. However, specific dosage ranges and methods claimed in 6,143,326 differentiate from prior art.
-
Non-Obviousness: The patent claims that specific combinations and administration protocols yield unexpected benefits, supporting non-obviousness.
Current Patent Landscape (Post-2000)
Post-issue, multiple patents have extended or built upon this patent's foundation:
- Method-of-use patents for specific dosing regimens.
- Patents covering new formulations or additional drug combinations in the same therapeutic space.
- Patent expirations (typically 20 years from filing) suggest the patent will expire in 2020s, opening the space for generics.
Implications for Market and R&D
- The patent solidified claims on a widely used combination therapy, influencing patenting strategies.
- The landscape shows frequent licensing, challenging the patent's enforceability.
- Current patents in the same space tend to focus on novel formulations or new combinations, not the original claims.
Summary
US Patent 6,143,326 claims a specific method and composition for hypercholesterolemia treatment involving statin and fibrate combination. While foundational in this space, its claims are constrained by existing earlier art and have been challenged by subsequent patent expirations. The patent landscape features related filings aimed at different lipid-lowering combinations and administration regimens, with legal protections waning as patents approach expiry.
Key Takeaways
- The patent offers a method-of-use for combination lipid therapy with defined formulations and dosing.
- It forms part of a dense patent landscape with prior art covering similar combinations.
- The patent's enforceability diminishes as it approaches expiration, enabling generics.
- Innovation in the field shifts toward novel formulations, new drug combinations, or delivery methods.
- Patent strategies in this space focus on extending claims through secondary patents and new therapeutic methods.
FAQs
1. When did the patent expire?
The US patent 6,143,326 filed on August 16, 1999, generally expires 20 years from the filing date, which would be August 16, 2019, subject to patent term adjustments. This means it is likely expired or nearing expiration.
2. Are the claims limited to specific statins?
The claims cover multiple statins, including lovastatin, pravastatin, and simvastatin, with dosage ranges and combinations defined explicitly.
3. Can generic formulations now be developed?
Yes, patent expiration permits generic development for the claimed compositions and methods, assuming no new applicable patent barriers.
4. Are there ongoing patents related to the same combination?
Subsequent patents focus on formulations, delivery systems, or novel combinations in the same class but often with different claims.
5. How does this patent influence current clinical practice?
While the patent contributed to the legal framework for combination lipid therapy, current practice primarily relies on established generics, with patent protections having expired.
References
[1] United States Patent and Trademark Office. Patent No. 6,143,326.
[2] European Patent Office. Patent EP0957051.
[3] World Intellectual Property Organization. Patent WO 99/67963.
[4] Kastelein, J. J., et al. (2000). "Combination lipid therapy: rationale and clinical evidence." American Heart Journal, 139(3), S132–S140.
